Biotech News
ATM Equity Purchases by Pulse Biosciences’ Co-Chairmen Total Approximately $13.3 Million
investors.pulsebiosciences.com2026-05-12 11:10 EST
HAYWARD, Calif. --(BUSINESS WIRE)--May 12, 2026-- Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced its Co-Chairmen of the Board, Robert Duggan and Chief Executive Officer Paul LaViolette,